La provisión de terapia de sustitución de opiáceos en combinación con la terapia antirretroviral para personas que se inyectan drogas da como resultado una reducción significativamente mayor de las muertes en comparación a la provisión de cualquiera de estas intervenciones por sí sola, según lo ha demostrado un estudio realizado en la provincia canadiense de Columbia Británica. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.


Providing opioid substitution therapy (OST) alongside antiretroviral therapy (ART) to people who inject drugs results in a significantly greater reduction in deaths compared to providing either intervention alone, a study of the Canadian province of British Columbia has shown.

The findings were presented by Dr Bohdan Nosyk and colleagues from the University of British Columbia Centre of Excellence in HIV/AIDS at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada.

Research from Ukraine, also presented at the conference, showed that people receiving opioid substitution therapy had better engagement with HIV care.

Opioid substitution therapy is recommended by the World Health Organization as a core element of the harm reduction and care package that should be provided for people who inject drugs after diagnosis with HIV infection. There are big variations worldwide in access to opioid substitution therapy for people living with HIV who inject drugs: a 21-country survey, published in 2013, found average coverage of just 3% for this population.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Thumbnail Flickr CC CSIS Centre for Strategic & International Studies